78967-81-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-1-(2,4-dichlorophenyl)butan-1-one is used as a potent opioid analgesic for its ability to produce prolonged and profound pain relief. Its high potency makes it a potential candidate for the development of new pain management therapies, although its classification as a Schedule I controlled substance limits its medical applications.
Used in Research and Development:
2-Bromo-1-(2,4-dichlorophenyl)butan-1-one serves as a valuable research compound for studying the mechanisms of opioid action and developing new drugs with improved safety profiles. Its extreme potency and unique chemical structure provide insights into the design of novel analgesics with reduced potential for abuse and addiction.
Used in Forensic Toxicology:
As a Schedule I controlled substance, 2-Bromo-1-(2,4-dichlorophenyl)butan-1-one is relevant in forensic toxicology for the detection and analysis of its presence in biological samples. This is crucial for identifying cases of drug abuse, overdose, or illegal distribution.

Upstream product

• 66353-47-7 1-(2,4-dichlorophenyl)butan-1-one 

Relevant academic research and scientific papers

Synthesis and biological activity evaluation of 1,2,3-thiadiazole derivatives as potential elicitors with highly systemic acquired resistance

Elicitors provide a broad spectrum of systemic acquired resistance by altering the physical and physiological status of the host plants and, therefore, are among the most successful directions in modern pesticide development for plant protection. To develop a novel elicitor with highly systemic acquired resistance, two series of thiazole- and oxadiazole-containing thiadiazole derivatives were rationally designed and synthesized according to the principle of combination of bioactive substructures in this work. Their structures were characterized by 1H nuclear magnetic resonance (NMR), infrared (IR), high-resolution mass spectrometry (HRMS), or elemental analysis. Their potential systemic acquired resistance as an elicitor was also evaluated; bioassay results indicated that, among the 23 compounds synthesized, three compounds, 10a, 10d, and 12b, displayed better systemic acquired resistance than the positive control, tiadinil, a commercialized 1,2,3-thiadiazolebased elicitor. In addition, three other compounds, 10f, 12c, and 12j, exhibited a certain degree of fungus growth inhibition In vitro or In vivo. Our results demonstrated that, in combination of bioactive substructures is an interesting exploration for novel pesticide development, thiazole-and oxadiazole-containing thiadiazole derivatives are potential elicitors with good systemic acquired resistance.